CHF medications: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
|'''Agent''' | |'''Agent''' | ||
|'''RA''' | |'''RA''' | ||
| Line 13: | Line 13: | ||
|- | |- | ||
| | | [[Isordil]] 60 | ||
| - | | - | ||
| - | | - | ||
| (-) | | (-) | ||
| - | | - | ||
| -/+ | | -/+ | ||
|- | |- | ||
| | | [[Hydralazine]] 100 | ||
| ~ | | ~ | ||
| ~ | | ~ | ||
| - | | - | ||
| +/- | | +/- | ||
| ++ | | ++ | ||
|- | |- | ||
| hy (MR/AI) | | hy (MR/AI) | ||
| - | | - | ||
| -- | | -- | ||
| ++ | | ++ | ||
| -/+ | | -/+ | ||
| +/- | | +/- | ||
|- | |- | ||
| ACEI | | [[ACEI]] | ||
| - | | - | ||
| - | | - | ||
| - | | - | ||
| +/- | | +/- | ||
| + | | + | ||
|- | |- | ||
| Minoxidil | | Minoxidil | ||
| ~ | | ~ | ||
| ~ | | ~ | ||
| -- | | -- | ||
| +/- | | +/- | ||
| ++ | | ++ | ||
|} | |} | ||
Revision as of 07:23, 6 June 2015
| Agent | RA | RCW | SVR | BP | CO |
| Isordil 60 | - | - | (-) | - | -/+ |
| Hydralazine 100 | ~ | ~ | - | +/- | ++ |
| hy (MR/AI) | - | -- | ++ | -/+ | +/- |
| ACEI | - | - | - | +/- | + |
| Minoxidil | ~ | ~ | -- | +/- | ++ |
- Carvedilol: decreases mortality 67%
- Digoxin: decrease syx/hospitaliz
- Aldactone in Class IV dec mortality
- Isordil: cor. VD; +BP if ischemia
- ISDN/HYDRA. decreased mortality in CHF
- ACEI GREAT mortality benefit
Target Doses
- Hydralazine: 100 TID start 25
- Isordil: 60-80 TID
- Captopril: 100 TID start 12.5
- Lisinopril/enalapril: 10 bid class II/III
- 20 bid class IV
- Carvedilol 25 BID; 50 BID if >80kg
- Digoxin: varies
- Spironolactone 25-50 qd
- Enalapril 1.25mg IV
- Nitroglycerin (Initial dose 5-10ug/min, increased every 3-5 minute to dose range 10-200ug/min)
- Nitroprusside (Initial dose 5-10ug/min, increased every 3-5 minute to dose range 5-400ug/min)
^Consider when need afterload reduction